Upcoming

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique entity identifier (UEI)) is allowed.

Funding Opportunity Description
The purpose of the National Library of Medicine (NLM) Institutional Training Program in Biomedical Informatics, Data Science, and Artificial Intelligence (AI) is to support pre-doctoral and postdoctoral training for research careers in fields which jointly advance information sciences and data-driven discovery. As the scale and complexity of biomedical and health data continue to grow, there is an increasing national need for a highly skilled workforce capable of developing innovative computational, statistical, and information science approaches to accelerate biomedical discovery and improve health. Graduates of NLM-supported T15 programs are expected to conduct original basic or applied research at the intersection of computer, statistical, and information sciences and one or more biomedical application domains, preparing them for research- and development-oriented roles in academic institutions, not-for-profit research institutes, governmental and public health agencies, biomedical and technology companies, and health care organizations.

Apply to Internal Competition // Limit: 2 // Tickets Available: 2

Limiting Language
An eligible organization can submit a maximum of two Written Proposals per Topic Announcement for Phase 0 as a lead organization. Senior/Key Personnel may be listed on a maximum of one Written Proposal per Topic Announcement. 

Topic Description
It is time for the next leap in the study of biology. By reliably linking protein sequence and structure to biological function, the United States can unlock a new era of biological engineering in which biological components are designed rather than discovered. Platform technologies that enable precise control over protein function will open the door to entirely new products and processes that use engineered biological components and outputs, such as enzymes. These capabilities will reshape the economics of biomanufacturing, chemical engineering, biosensing, and agriculture, among other sectors. 

Although recent advances allow us to predict the static structure of proteins, we lack insight into their dynamic behavior. Even in minimal cells, the function of many genes and proteins remains unknown. NSF X-Labs in this space will close that gap by creating platform technologies that enable the intentional design of individual proteins or entire genomes whose function is predictable and/or controllable. Teams will pioneer and integrate advances in protein design/synthesis, genome assembly, synthetic cells, or experimental functional discovery and validation. Additionally, NSF X-Labs might use super intelligence (SI) to dramatically accelerate our ability to engineer the behavior of designed proteins or synthetic cells, including their metabolic requirements, stability, functional outputs, by-products, or system-level interactions.  

Examples of relevant Missions include, but are not limited to: the creation of models that enable the prediction of protein–molecule interactions, including novel approaches to the collection or integration of SI training data; the design and application of nanoscale protein-based molecular motors; an enzyme function platform to discover and engineer enzyme pathways that have specific molecular behaviors; and a synthetic cell/genome platform to design and instantiate genomes with predictable and controllable biological function.  

An NSF X-Labs Mission in this Topic must be transformative, accelerating breakthroughs in our understanding of the relationship between sequence and function, and catalyzing capabilities to engineer proteins or entire genomes with exceptional new capabilities. Successful teams will develop platform technologies, demonstrate measurable impact on the U.S. biotechnology landscape, and position their technologies for widespread use by overcoming technical barriers that limit implementation and investment. Although NSF X-Labs in this space will have widespread applicability, each team should identify 2-3 high-utility domains and should eventually establish projects in them. Teams proposing to this topic should identify how their approach to biosafety and biosecurity is tailored to their Mission and its pilot application domains including an assessment of dangerous gain-of-function and an accompanying plan to mitigate unintended consequences. 

Examples of challenges not considered in scope for this Topic include: development of technologies where the impact is narrow and not widely deployable; fundamental research without potential for application in platform technologies; incremental advancement of the state of the art; standalone predictive models that do not generate or integrate new experimental data; and advancement of technologies that are already developed or supported by existing R&D investments by the U.S. public or private sectors. 

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique UEI or NIH IPF number) is allowed.

Purpose
The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines. The goal is to achieve long-lasting, highly effective protection that can save lives, strengthen public health security in the United States, and serve as a model for, or are potentially effective against, other mosquito-borne diseases. 

Full sponsor guidelines are linked here.

Apply to Internal Competition // Limit: 3 // Tickets Available: 3

Limiting Language 
The Mathers Foundation Grants Program is a limited competition, where eligible organizations may submit up to three (3) institute-nominated Letter of Inquiry (LOI) applications per grant cycle. 

Program Overview
Full sponsor guidelines are linked here.

The mission of The G. Harold and Leila Y. Mathers Foundation is to advance knowledge in the life sciences by sponsoring scientific research that will benefit mankind. The foundation’s grants program seeks to support basic science, ideally with potential translational applications. Immunology, microbiome, genomics, structural biology, cellular physiology, neuroscience, etc., are some noteworthy examples of current research support.

For many years the Foundation has enjoyed special recognition in the research community for supporting “basic” scientific research, realizing that true transformative breakthroughs usually occur after a thorough understanding of the fundamental mechanisms underlying natural phenomena. More recently, and with the advent of newer investigative methodologies, technology, and tools, the Foundation now embraces innovative translational research proposals.

The grant duration must be three years. The budget should be reasonable based on the aims of the project. Indirect costs may not exceed 10%. Preliminary Budgets are required during the LOI phase. A detailed budget justification is not required until the proposal phase. The Foundation’s grant award is not intended to be utilized for purchasing capital equipment (“bricks-and-mortar”) for the lab and is intended only to support the actual investigation. The Foundation assumes and expects that capital equipment must be provided by the research institution or university.

Application Guidance:

• Grant budgets cannot exceed $600-750K
• The Foundation primarily supports basic science, ideally with potential translational applications.
• Immunology, microbiome, genomics, structural biology, cellular physiology, neuroscience, etc., are some noteworthy examples of current research support.
• Covid-19-related research projects (aims or sub-aims) will not be considered for support.
• Medical imaging technology-related projects and/or electrical engineering technology development projects will not be considered for support.
• Plant Biology Research, Oceanography, Space Exploration. and Global warming-related research will not be considered for support.
• As technology continues to advance, it is apparent that investigations in the area of basic science and translational research may become more and more reliant on collaborative, interdisciplinary projects. It is important to note that any interdisciplinary project proposals may require additional information regarding the collaborator(s)’ achievements and relevant expertise.
• Feedback for declined LOI Requests will not be provided; LOIs or Formal Proposals that have been declined should not be resubmitted at a later date for consideration.
• Renewal applications for the same or related research will not be accorded priority consideration. It is strongly advised that any re-application for grant renewal consider a new direction based on prior research or emphasize some new potential translational aspects and not merely an extension of previously funded research.
• Requests for funding previously federally supported research and/or applications pending federal approval will not be accorded priority consideration.
• Requests for support of clinical trials or drug discovery will not be approved. The Foundation will not support projects which we consider pre-clinical drug development.

Please note, while RDS and SPS will manage submitting the institutional nomination, it is the responsibility of the selected faculty members to complete the portal registration by the January 28, 2027 at 8pm EST deadline.

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Limiting Language 
Only one application per institution (normally identified by having a unique entity identifier (UEI) number or NIH IPF number) is allowed

Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms.

To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through investigational new drugs (IND) studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: (1) novel agents or (2) agents or combinations approved for other indications and repurposed for treatment of GBM following appropriate preclinical studies. The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.

Apply to Internal Competition // Limit: 1 // Tickets Available: 1 

Limiting Language
Only one application per institution is allowed.

Program Description
The overall goal of this program is to accelerate scientific discovery, improve research efficiency, and enhance the translation of research findings into improved health outcomes. Centers funded under this program will also foster multidisciplinary collaboration, support workforce development across career stages, and promote training in emerging areas such as data science, artificial intelligence, and implementation research. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS P30 Centers Program to support integrated research Centers within its mission areas of skin biology and diseases; bone, muscle, and orthopaedic research; and rheumatic diseases.

The NIAMS P30 Centers Program supports Centers that provide coordinated research infrastructure, shared resources, and methodological expertise to advance basic, translational, and clinical research.

These Centers are expected to integrate state-of-the-art research resources with capabilities that support clinical and translational research, including the development, testing, and dissemination of novel analytical methods, study designs, outcome measures, and data-driven approaches.

Full sponsor guidelines are linked here.

Apply to Internal Competition // Limit: 2 // Tickets Available: 2

Limiting Language
Each eligible institution may submit a maximum of two proposals for the 2027–2028 funding cycle.
 

Overview
The ASCENDR Research Program is a competitive, faculty-led program designed to advance research aligned with the U.S. Department of War’s (DoW) science and technology priorities. Through targeted research funding, faculty across HSRU Alliance institutions will lead projects that address real-world defense challenges while engaging graduate students in meaningful research experiences. The program supports the development of innovative solutions in key technical areas and fosters deeper collaboration between academic researchers and the defense enterprise.

Critical Technology Areas
For the 2027–2028 funding cycle, proposed research must contribute to one or more of the six DoW Critical Technology Areas identified for this competition. Proposals may address a Critical Technology Area directly or advance foundational, enabling, or cross-cutting research with a clearly articulated connection to one or more of the areas

1. Applied Artificial Intelligence (AAI)
   Research that advances the effective application of artificial intelligence, machine learning, data analytics, and related computational methods to improve decision-making and operational efficiency. Relevant research may include algorithms, data methods, autonomy, human-machine teaming, modeling and simulation, trustworthy and assured AI, and approaches that enable reliable AI adoption across defense domains.
2. Biomanufacturing (BIO)
   Research that harnesses living systems, biological processes, and bioengineering to produce critical materials, substances, or capabilities at scale. Relevant research may include bioprocess development, synthetic biology, biofabrication, scale-up, quality and reproducibility, and approaches that reduce supply-chain vulnerabilities and strengthen resilience.
3. Contested Logistics Technologies (LOG)
   Research that enables forces to operate and sustain missions when transportation, supply networks, communications, or infrastructure are disrupted, degraded, or denied. Relevant research may include energy storage and power systems, resilient supply networks, predictive logistics, autonomous or distributed resupply, maintenance and sustainment, and production at the point of need.
4. Quantum and Battlefield Information Dominance (Q-BID)
   Research that advances technologies needed to maintain information advantage in degraded or denied environments, including resilient communications, precision navigation and timing, sensing, and electromagnetic-spectrum maneuverability. Relevant research may draw on quantum science and engineering, radio-frequency technologies, photonics, radar and electronic warfare, secure networks, signal processing, and other approaches that improve the availability, accuracy, and survivability of battlefield information.
5. Scaled Directed Energy (SCADE)
   Research that advances scalable and affordable high-energy laser and high-power microwave capabilities for the precise neutralization of threats. Relevant research may include energy sources, materials and components, power and thermal management, beam generation and control, modeling and testing, manufacturability, and approaches that overcome cost and production barriers.
6. Scaled Hypersonics (SHY)
   Research that enables the affordable and scalable development of systems operating at Mach 5 or greater. Relevant research may include propulsion, aerothermodynamics, high-temperature materials and structures, thermal protection, guidance, navigation and control, sensing, modeling and simulation, testing, and manufacturing approaches that improve speed, precision, survivability, and production at scale

Eligibility

The proposal must originate from an HSRU member institution in good standing.

• Principal Investigator and Co-Principal Investigator(s) must be a Research Faculty member or Tenure/Tenure Track Faculty member that is early to mid-career, defined as within the first 8 years of their professional research career.     
• The Principal Investigator must hire and integrate at least one Graduate Research Assistant for this project. The graduate assistant must be enrolled at the start of the project and maintain enrollment eligibility throughout the proposed project.  
• All PIs, Co-PIs, and the graduate assistant working on this project must be U.S. Persons, defined as U.S. born or U.S. Naturalized Citizens.
• The Principal Investigator and Co-PIs must agree to jointly participate in the ASCENDR Leadership Program.

Full sponsor guidelines are linked here.

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Limiting Language
An organization may submit only one application under this notice.

If you submit multiple applications, NEH will accept only your last validated submission prior to the deadline under the applicable Grants.gov funding opportunity.

Purpose
NDNP is a partnership between NEH and the Library of Congress (LOC) to create a national digital resource of historically significant newspapers published between 1690 and 1963, from all 56 states and U.S. jurisdictions. LOC will permanently maintain this freely accessible, searchable online database (Chronicling America: Historic American Newspapers). An accompanying national newspaper directory of bibliographic and holdings information directs users to newspaper titles available in all formats. LOC also will digitize newspaper pages drawn from its own collections and contribute them to Chronicling America.

If your application is successful, you will select newspapers published in states or jurisdictions between 1690 and 1963 and, over a period of two years, convert approximately 100,000 pages into digital files (preferably from microfilm), according to the technical guidelines outlined by LOC. 

NEH welcomes applications that involve collaboration between state and jurisdictional partners, which might involve arrangements to manage the creation and delivery of digital files; regular and ongoing consultation about project management; or formal training for project staff. States and jurisdictions are encouraged to digitize titles published within their current geographic boundaries, including those from Native American Tribal nations, but cases for digitization beyond such boundaries can be made. For example, a state may digitize Native American newspapers that were published in another state, or a state may partner with a jurisdiction to digitize the newspapers from there. If you propose to digitize titles published outside of what is now your state or jurisdiction, you must provide the rationale for doing so. 

NDNP supports dissemination activities that engage the wider public in exploring the digitized content, within limits. Your budget may include staff time, consultation with outside experts, and other eligible expenses related to disseminating NEH-funded products, but the primary purpose of this program is to create a national digital resource of historically significant newspapers. 

Your proposed project must include an advisory board. The advisory board could include scholars, teachers, traditional knowledge keepers, librarians, and archivists at a variety of institutions, and the board should be involved in selecting the newspapers to be digitized. The advisory board should also help disseminate information about the project’s progress and Chronicling America more generally. NEH has programmatic expectations depending on how many NDNP awards your state or jurisdiction has previously received and will consider the number of previous NDNP awards when making funding decisions.

Full sponsor guidelines are linked here. 

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Limited Language
This is a limited submission opportunity: each institution may nominate ONE applicant for this funding opportunity 

Program Overview
At Susan G. Komen®, we are committed to saving lives by meeting the most critical needs in our communities and investing in breakthrough research to conquer deadly and aggressive breast cancers. We are determined to change the unacceptable reality that each year about 43,000 people in the U.S. will die from breast cancer. As part of this goal, we are focused on improving the care and outcomes for people with inflammatory breast cancer (IBC), a rare and highly aggressive form of breast cancer.  

IBC is characterized by tumor cell emboli blocking the breast lymph vessels. This blockage causes inflammatory-like changes in the breast, including swelling and skin reddening. The American Joint Committee on Cancer (AJCC) guidelines define IBC by the rapid onset (less than 6 months) of erythema occupying at least 1/3 of the breast, edema, peau d’ orange (orange peel-like appearance) and/or warmth (with or without an underlying mass), and pathologic confirmation of invasive carcinoma. Although IBC has been recognized as a distinct form of breast cancer for over a century, its etiology and underlying biological mechanisms remain poorly understood. Consequently, no validated, widely adopted IBC-specific biomarkers or targeted therapies exist, and current management is largely informed by evidence from non-IBC breast cancer. This limited understanding of IBC biology remains a significant barrier to the development of more precise diagnostic and therapeutic approaches, highlighting the need for research focused on the unique mechanisms driving the disease. Therefore, the goal of the Inflammatory Breast Cancer (IBC) Research Grant is to support innovative, hypothesis-driven research that advances our understanding of the biological underpinnings of IBC and opens new avenues of investigation into the disease.  

To identify areas where investment could have the greatest impact, the Susan G. Komen-IBCRF IBC Collaborative, in partnership with the Milburn Foundation, convened the Biology of IBC Task Force, a group of IBC researchers and patient advocates. The Task Force identified three broad areas of scientific opportunity that require significant investigation to advance the field: 

• 1. IBC onset and development, including studies focused on the tumor and host microenvironment, epigenetic and proteomic drivers of disease, host genetic factors and biological contributors to health disparities. 

  2. IBC metastatic dissemination, including mechanisms of cell migration and mobility, biological characteristics associated with therapeutic response and the role of tumor and host, epigenetic and proteomic factors in IBC disease progression. 

  3. IBC monitoring and detection, including approaches to detect minimal residual disease (MRD), improve prognostication, assess therapeutic response and advance theragnostic strategies. 

Eligibility 
Applicant/PIs and Institutions must conform to the following eligibility criteria to apply for an Inflammatory Breast Cancer Research Grant. Grants will be awarded to a single Principal Investigator (PI). Co-Principal Investigators (Co-PIs) are not allowed. CoInvestigators are permitted. 
Applicant/PI 

• Must be nominated as the sole Applicant/PI from their institution by the Institution’s Office of Sponsored Programs, Grants Office, or equivalent. This is a limited submission opportunity, and the Applicant/PI cannot self-nominate.  
• Must have a doctoral degree, such as M.D., Ph.D., D.Ph., D.O. or equivalent. 
• Must hold a full-time faculty appointment or have a formal offer letter from the Institution that confirms position and start date by the Full Application due date (January 18, 2027), documented by the Applicant/PI Biosketch.  
• May NOT be the PI of an active Komen Grant that includes specific aims or objectives focused on IBC at the Full Application due date (January 18, 2027).  
• May NOT be the PI of two or more active Komen Grants at the Full Application due date (January 18, 2027) 
• Must ensure that all past Komen-funded Grants are up to date and in compliance with all Komen requirements, e.g., progress and financial report submissions, IRB approvals, etc. by the Full Application due date (January 18, 2027), if applicable. 
• Is not required to be a U.S. citizen or permanent resident. 
• The institution-nominated Applicant/PI may submit only one Letter of Intent in response to this funding announcement.  

Apply to Internal Competition // Limit: 1 (Lead Applicant) // Tickets Available: 1

Limiting Language
You can submit only one application for this NOFO. If you submit more than one, we will only review the last timely submission. Any other submissions listing the same entity as the applicant for the same topic area will not be eligible. This limitation does not prohibit you from collaborating on other applications (e.g., as a potential subrecipient or partner) if you are not listed as the applicant on more than one application for each topic area of this NOFO.

Executive Summary
The goal of this award is to develop a potentially revolutionary Light Water Reactor (LWR) Silicon Carbide (SiC) cladding material that can withstand significant accident and transient conditions. This program seeks to support research and development of SiC cladding technology, including mechanical, thermal-hydraulic, high temperature, and corrosion testing for both unirradiated and irradiated SiC cladding samples. This will provide the useful performance data to enable future commercial lead test rods (LTRs) irradiation testing. Irradiation campaigns in research reactors (e.g., INL ATR, ORNL HFIR, MITR) and Post Irradiation Evaluations (PIEs) are expected to provide irradiation performance data for fuel vendor licensing and accident analyses methods needed for NRC licensing review. Improvements in SiC/SiC composite cladding fabrication methods are expected to be made.

Full sponsor guidelines are linked here.